Documents
Folders (1)
Name |
---|
Files(78)
Name | Size/Type | Description | Date |
---|---|---|---|
Guidelines for Management of Patients receiving Treatment Doses of Low Molecular Weight Heparins (exp May 27) MMG032 | 348KB PDF | To provide guidance on the management of patients prescribed treatment doses of low molecular weight heparins to reduce the risk of harm from incorrect prescribing and administration. | 05 Nov 2024 |
Guidelines for managing diabetes in early psychosis (Mar24-Mar27) MMG042.pdf | 90KB PDF | Guidelines for managing diabetes in early psychosis | 06 Nov 2024 |
Guidelines for managing thyroid dysfunction in early psychosis (Mar24-Mar27) MMG041 .pdf | 688KB PDF | Guidelines for managing thyroid dysfunction in early psychosis | 06 Nov 2024 |
Guidelines for Monitoring of Antimanic and Prophylactic Medication in Bipolar Disorder (exp Sept 27) MMG023 | 564KB PDF | To provide guidance for prescribers on the monitoring required for patients on medicines used to prevent and treat mania in bipolar disorder | 16 May 2025 |
Guidelines for Out of Hours Treatment of Opioid Dependent Patients on Inpatient Wards (exp May 27) MMG028 | 281KB PDF | To provide advice for Doctors for the initial treatment of opioid dependent patients on admission | 06 Nov 2024 |
Guidelines for Prescribing Oral Methotrexate (exp Sept 26) MMG031 | 360KB PDF | To provide guidance on the management of patients prescribed oral methotrexate, to reduce the risk of harm from incorrect prescribing administration or monitoring of methotrexate. | 06 Nov 2024 |
Guidelines for the Clinical Management of Valproate v1 (Sep24-Sep27) MMG043.pdf | 333KB PDF | To ensure prescribing adheres to all regulatory measures as advised by the MHRA which came into force in January 2024 | 27 Nov 2024 |
Guidelines for the Management of Antipsychotic-induced Hyperprolactinaemia (exp Nov 25) MMG007 | 510KB PDF | This document provides guidance to prescribers on the management of hyperprolactinaemia related to antipsychotic use. | 06 Nov 2024 |
Guidelines for the Management of Diabetes during the end of Life (Review Sept 25) MMG010 | 383KB PDF | This guidance has been developed to aid healthcare professionals working in the specialist field of palliative care to ensure adults aged 18 or over with diabetes who are nearing the end of life have good glycaemic control in the inpatient setting. | 06 Nov 2024 |
Guidelines for the use of Antipsychotic drugs in the treatment of Schizophrenia (exp Nov 26) MMG009 | 785KB PDF | To provide guidance on the prescribing of antipsychotics in patients with schizophrenia. | 06 Nov 2024 |
Guidelines for the use of hypnotics for the treatment of insomnia (exp Sept 25) MMG003 | 445KB PDF | To provide guidance on the appropriate and safe use of hypnotics in controlling insomnia | 06 Nov 2024 |
Guidelines for the use of topical morphine for painful skin ulcers in palliative care (exp Nov 26) MMG029 | 353KB PDF | To provide guidance on the use of topical morphine for painful skin ulcers in Specialist Palliative Care. | 06 Nov 2024 |
Guidelines for the use of Zuclopenthixol Acetate Injection (review May 25) MMG006 | 315KB PDF | To provide guidance on the prescribing and use of zuclopenthixol acetate injection. | 06 Nov 2024 |
Guidelines for use of clozapine in patients with Covid-19 (exp Sep 25) MMG039.pdf | 376KB PDF | This document sets out a pragmatic clinical practice guideline for clinicians providing healthcare in NHFT to support the safe management of clozapine use in those who have tested positive for COVID-19 | 06 Nov 2024 |
Guidelines for use of primary thromboprophylaxis in the palliative care setting (Review July 2025) MMG015 | 381KB PDF | The aim of this guidance is to aid clinical decision making regarding primary thromboprophylaxis for VTE in patients with malignant and non-malignant conditions in the palliative care setting. | 06 Nov 2024 |
Guidelines of the use of high dose Antipsychotic Medication (exp Nov 26) MMG012 | 536KB PDF | To provide guidance on the recognition of high dose antipsychotic regimes and the associated monitoring requirements for all patients prescribed high dose antipsychotics for serious mental health in the in-patient and outpatient NHFT services. | 06 Nov 2024 |
High Dose Venlafaxine and Combination of Venlafaxine and Mirtazapine (Review Sept 25) MMG004 | 371KB PDF | To provide guidance on the use of high dose venlafaxine and the combination of venlafaxine and mirtazapine in the treatment of depression. | 06 Nov 2024 |
Inpatient Alcohol Detoxification (exp July 25) MMG013 | 787KB PDF | To provide guidance on the management of alcohol detoxification on inpatient units. | 06 Nov 2024 |
Intravenous Therapy Protocol v4.2 exp Sept 25 amended Oct 24 MMPr031.pdf | 722KB PDF | This Protocol provides a framework from which services can be delivered safely, effectively and will provide guidance for the appropriate care of patients requiring medication via the intravenous route and the care of all vascular access devices | 14 May 2025 |
Local Procedure for Prescribing, Dispensing and Administering Medications in Learning Disability Short Breaks v4.2 (exp Nov 25) MMPr009 | 1808KB PDF | This document sets out the procedures to be followed when prescribing, dispensing and administering medicines within the short breaks service and will be implemented in the directorate’s short breaks services countywide. | 27 Mar 2025 |